These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

871 related items for PubMed ID: 26207892

  • 1. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M.
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [Abstract] [Full Text] [Related]

  • 2. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [Abstract] [Full Text] [Related]

  • 3. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [Abstract] [Full Text] [Related]

  • 4. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
    Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.
    Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
    [Abstract] [Full Text] [Related]

  • 5. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [Abstract] [Full Text] [Related]

  • 6. Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
    Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, Napolitano F, di Maio A, Mellone M, Stanic J, Tronci E, Fidalgo C, Stancampiano R, Carta M, Calabresi P, Gardoni F, Usiello A, Picconi B.
    Neurobiol Dis; 2016 Feb; 86():140-53. PubMed ID: 26639853
    [Abstract] [Full Text] [Related]

  • 7. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [Abstract] [Full Text] [Related]

  • 8. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    F Hernández L, Castela I, Ruiz-DeDiego I, Obeso JA, Moratalla R.
    Mov Disord; 2017 Apr; 32(4):530-537. PubMed ID: 28256089
    [Abstract] [Full Text] [Related]

  • 9. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
    Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M.
    J Neurosci; 2012 Nov 14; 32(46):16106-19. PubMed ID: 23152595
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 14; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA, Zhang D, Bordia T, Quik M.
    Mov Disord; 2017 Apr 14; 32(4):538-548. PubMed ID: 28256010
    [Abstract] [Full Text] [Related]

  • 20. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F, Marti M, Bido S, Cenci MA, Morari M.
    Neurobiol Dis; 2012 Jan 14; 45(1):573-82. PubMed ID: 22001605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.